{"filings":[{"id":92905,"accession_number":"0001477932-26-001957","cik":1443863,"company_name":"BioCorRx Inc.","ticker":"BICX","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"BioCorRx acquires additional 12.15% of subsidiary via stock-for-stock exchange with insiders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered stock exchange agreement with CEO, President, and board member to transfer 1,215 subsidiary shares for 2,263,371 parent shares.","Exchange closed March 27, 2026; intended as tax-free reorganization under Section 368(a)(1)(B).","Subsidiary BioCorRx Pharmaceuticals was ~12.15% minority stake acquired; no cash consideration paid.","Parent shares are unregistered, issued under Section 4(a)(2) exemption; registration rights granted to shareholders.","Part of Plan of Reorganization to obtain control of subsidiary under Section 368(c) of the Code."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":11012053.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136968,"accession_number":"0001477932-25-005396","cik":1443863,"company_name":"BioCorRx Inc.","ticker":"BICX","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"BioCorRx enters $350K securities purchase agreement for 1M shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aggregate purchase price of $350,000 for 1,000,000 shares of common stock and warrants to purchase up to 1,000,000 shares.","Warrant exercise price $0.35 per share, exercisable for five years from issuance (July 29, 2025).","Transaction not yet closed; agreement provides piggyback registration rights for the Shares and Warrant Shares.","Securities issued to accredited investors under Section 4(a)(2) exemption; no public offering.","Offering in two tranches; Second Tranche subject to 60-day due diligence period post Initial Closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":11012053.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172826,"accession_number":"0001477932-25-001603","cik":1443863,"company_name":"BioCorRx Inc.","ticker":"BICX","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"BioCorRx acquires FDA-approved opioid withdrawal drug Lucemyra from USWM LLC","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront purchase price of $400,000 paid via seller retention of 50% of net sales and net distributable profits until capped.","BioCorRx issued 500,000 shares of common stock and a warrant for 500,000 shares at $1.00 exercise price, 2-year term.","Lucemyra is first and only non-opioid FDA-approved medication for opioid withdrawal; BioCorRx expects meaningful sales and positive cash flow.","BioCorRx will pay a low single-digit royalty to USWM on future sales; no direct cash payment at closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11012053.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206347,"accession_number":"0001477932-24-004147","cik":1443863,"company_name":"BioCorRx Inc.","ticker":"BICX","form_type":"8-K","filed_at":"2024-07-10T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"BioCorRx dismisses Marcum LLP auditor, appoints M&K CPAS; prior reports flagged going concern","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board dismissed Marcum LLP and engaged M&K CPAS as independent auditor for fiscal 2024.","Marcum's reports for 2022 and 2023 included an explanatory paragraph regarding going concern; no adverse opinions.","No disagreements or reportable events occurred with Marcum during its engagement.","No consultation with M&K on accounting principles or reportable events prior to engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":11012053.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223455,"accession_number":"0001477932-24-001846","cik":1443863,"company_name":"BioCorRx Inc.","ticker":"BICX","form_type":"8-K","filed_at":"2024-04-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Two directors resign from BioCorRx board; no stated disagreements","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brady Granier resigned from board effective March 31, 2024.","Harsha Murthy resigned from board effective April 2, 2024.","Both resignations not due to any disagreement with Company or subsidiary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":11012053.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242900,"accession_number":"0001477932-24-000065","cik":1443863,"company_name":"BioCorRx Inc.","ticker":"BICX","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"BioCorRx President Brady Granier resigns; Louis Lucido appointed as President","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brady Granier resigned as President of BioCorRx and CEO of BioCorRx Pharmaceuticals, effective Jan 31, 2024; remains on board.","Louis Lucido appointed Interim President from Jan 5, 2024, then President from Feb 1, 2024; remains board member.","Lucido to receive $200,000 annual compensation paid in equity monthly (~$16,667 in shares based on 3-day avg closing price).","Lucido, 75, formerly COO of DoubleLine Group and founding partner; director since March 2019.","Granier's resignation not due to any disagreement with the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":11012053.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260264,"accession_number":"0001477932-23-009154","cik":1443863,"company_name":"BioCorRx Inc.","ticker":"BICX","form_type":"8-K","filed_at":"2023-12-15T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"BioCorRx raises $200K via note, warrant & inducement shares; note matures Sep 2024","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $220K principal note (8% OID) for $200K cash; unsecured, matures Sep 8, 2024.","Six monthly amortization payments of $39,600 starting Apr 8, 2024; prepayable without penalty.","Issued 4-year warrant for 200K shares at $2.00/share exercise price.","Issued 24,000 restricted common shares as inducement.","Securities issued in private placement under Section 4(a)(2) to a single accredited investor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11012053.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260263,"accession_number":"0001477932-23-008570","cik":1443863,"company_name":"BioCorRx Inc.","ticker":"BICX","form_type":"8-K","filed_at":"2023-11-16T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"BioCorRx raises $200K from LGH via $220K note, warrant, and 24K inducement shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold $220K promissory note (8% one-time interest) for $200K purchase price; $20K OID.","Issued 4-year warrant to buy 200K shares at $2.00/share.","Issued 24,000 restricted shares as inducement.","Note amortizes in 6 monthly installments of $39,600 starting March 10, 2024; matures August 10, 2024.","Securities sold in unregistered exempt transaction to accredited investor; no collateral."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":11012053.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260262,"accession_number":"0001477932-23-008060","cik":1443863,"company_name":"BioCorRx Inc.","ticker":"BICX","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioCorRx President Brady Granier takes paid leave; CEO Lourdes Felix assumes duties","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["President Brady Granier granted paid administrative leave from Oct 30, 2023 to Jan 30, 2024; remains on board.","CEO/CFO Lourdes Felix assumes Granier's responsibilities effective Oct 30; compensation unchanged.","Leave period spans three months; no other officer changes disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":11012053.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295517,"accession_number":"0001477932-23-002411","cik":1443863,"company_name":"BioCorRx Inc.","ticker":"BICX","form_type":"8-K","filed_at":"2023-04-11T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"BioCorRx raises $300K via common stock and warrant sale to accredited investor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 174,409 shares of common stock at $1.72/share for total proceeds of $300,000.","Issued a warrant to purchase 174,409 shares at $4.00/share, exercisable for 3 years.","Securities issued in a private placement exempt from registration under Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":11012053.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295516,"accession_number":"0001477932-23-002272","cik":1443863,"company_name":"BioCorRx Inc.","ticker":"BICX","form_type":"8-K","filed_at":"2023-04-05T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"BioCorRx raises $600k from directors via stock and warrants; converts $314k note to equity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors Galligan and Lucido each invest $300k at $1.75/share, receive warrants for equal shares at $4.00.","Lucido exchanges $313,892 promissory note for 183,606 shares of common stock, canceling the note.","Total shares issued: 342,592 from subscriptions plus 183,606 from note exchange = 526,198 shares.","Warrants exercisable for 3 years at $4.00 per share, issued to both directors.","Securities issued in private placement exempt from registration under Section 4(a)(2)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":11012053.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316063,"accession_number":"0001477932-23-000474","cik":1443863,"company_name":"BioCorRx Inc.","ticker":"BICX","form_type":"8-K","filed_at":"2023-01-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"BioCorRx appoints Harsha Murthy to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Harsha Murthy appointed as director effective January 20, 2023.","Quarterly cash stipend of $15,000; additional $5,000 quarterly stock grant.","Indemnification agreement signed with Murthy per Nevada law.","Murthy serves as independent contractor; term ends at next annual meeting or earlier events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":11012053.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334365,"accession_number":"0001477932-22-007951","cik":1443863,"company_name":"BioCorRx Inc.","ticker":"BICX","form_type":"8-K","filed_at":"2022-10-27T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"BioCorRx changes independent auditor to Marcum LLP after Friedman merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Friedman LLP combined with Marcum LLP effective Sept 1, 2022; BOD engaged Marcum LLP on Oct 21, 2022 for FY2022 audit.","Friedman's audit reports for 2020 and 2021 included a going concern explanatory paragraph; no adverse opinions or modifications.","No disagreements or reportable events during the two most recent fiscal years or subsequent interim period before Friedman's merger.","Friedman formally resigned as independent registered public accounting firm on October 21, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":11012053.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369240,"accession_number":"0001477932-22-004297","cik":1443863,"company_name":"BioCorRx Inc.","ticker":"BICX","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BioCorRx ordered to pay $235,886 in legal fees to Pellecome; Company files appeal","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Court entered judgment against BioCorRx for $235,886 in costs and attorneys' fees, plus 10% annual interest from Oct 6, 2021.","Judgment follows a 2019 lawsuit that was dismissed without prejudice in July 2021.","BioCorRx filed a notice of appeal on May 27, 2022; outcome is uncertain.","Company has not yet paid any amount to Pellecome."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":11012053.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369239,"accession_number":"0001477932-22-003234","cik":1443863,"company_name":"BioCorRx Inc.","ticker":"BICX","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"BioCorRx raises $250K in private placement of stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 110,619 common shares at $2.26/share to accredited investor on May 6, 2022.","Issued warrant to purchase up to 165,929 shares at $6.00/share for 3 years.","Aggregate consideration received was $250,000.","Agreement entered May 5, became effective upon payment May 6."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":11012053.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369238,"accession_number":"0001477932-22-002702","cik":1443863,"company_name":"BioCorRx Inc.","ticker":"BICX","form_type":"8-K","filed_at":"2022-04-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"BioCorRx adopts 2022 Omnibus Plan authorizing 695,000 shares for equity incentives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved 2022 Omnibus Securities and Incentive Plan on April 22, 2022; replaces 2018 plan.","Plan reserves 695,000 shares of common stock for future equity awards.","Non-employee director annual compensation cap set at $300,000 (equity + cash).","Outstanding 2018 plan awards continue; forfeited shares become available under 2022 plan.","Plan permits options, restricted stock, units, performance units, SARs and distribution equivalent rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":11012053.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388438,"accession_number":"0001477932-22-000348","cik":1443863,"company_name":"BioCorRx Inc.","ticker":"BICX","form_type":"8-K","filed_at":"2022-01-19T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"BioCorRx raises $1M via private placement of 229,886 shares at $4.35/share to two directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $1M from sale of 229,886 shares at $4.35 per share to Lucido and Galligan trusts.","Both investors are BioCorRx board members; Louis Lucido and Joseph Galligan are the trustees.","Use of proceeds: 48% for legal fees from Buchalter; 52% for general working capital and administration.","Agreements became effective on January 12 (Lucido) and January 19 (Galligan) upon cash payment.","Shares are restricted securities issued under Rule 506 of Regulation D and bear appropriate legends."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11012053.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":425382,"accession_number":"0001477932-21-006115","cik":1443863,"company_name":"BioCorRx Inc.","ticker":"BICX","form_type":"8-K","filed_at":"2021-09-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioCorRx awarded $3.5M NIDA grant for first-in-human trial of BICX104 implant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Award of ~$3.5M from NIDA for second phase (UH3) of grant; total NIDA funding now ~$5.7M.","Funding supports first-in-human clinical trial of BICX104, an implantable naltrexone pellet for opioid use disorder.","Company previously received FDA clearance to proceed to human trials; aims to begin trial in 2021.","Grant is non-dilutive, covering substantial costs toward FDA approval for BICX104."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11012053.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}